According to the Prostate Cancer Working Group 3 (PCWG3) criteria, the first response evaluation should take place after 12 weeks of therapy by biochemical (i.e., serum prostate-specific antigen (PSA) changes), radiologic and clinical response assessment [8]. This evidence concerns the gene KLK3 and Familial prostate cancer.